Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: results of the cisfrad (gortec 2015-02) randomized phase ii trial

HIGHLIGHTS

• What: The 4-day fractionated regimen did not significantly increase the cumulative dose of cisplatin administered concurrently with radio­ therapy compared to the standard schedule.
• Who: Christian Borel from the Strasbourg, FranceLaboratory of Bioimaging and Pathology, University of Strasbourg, CNRS, Illkirch, France have published the Article: Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial, in the Journal: (JOURNAL) of July/15,/2020
• How: Technical aspects of the cisplatin pharmacokinetic study are described in Appendix 1 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.